Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-BID vs AMINOPHYLLINE DYE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm associated with asthma, chronic bronchitis, emphysema, and COPD,Apnea of prematurity (off-label)
Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
Terminal elimination half-life: 3-15 hours (mean ~10 hours in adults; 20-30 hours in neonates; 1-5 hours in smokers). Clinically, half-life decreases with smoking, increases with hepatic disease, heart failure, and certain drugs (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by CYP2E1 and xanthine oxidase.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4, CYP2E1, and CYP2D6. Metabolism may be saturated, leading to nonlinear kinetics at therapeutic doses.
Renal: 90% as metabolites (caffeine, theobromine, paraxanthine, and unchanged drug; 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine). Biliary/fecal: <10%.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
~40% bound to albumin.
Approximately 40% bound, primarily to albumin. In neonates, protein binding is lower (about 30%).
0.45 L/kg (range 0.3-0.7 L/kg). Distributes into total body water; higher Vd in neonates and patients with hepatic cirrhosis.
Approximately 0.5 L/kg (range 0.3-0.7 L/kg). Higher in premature infants and neonates (0.6-0.9 L/kg). Vd corresponds to total body water; aminophylline distributes into extracellular and intracellular fluid.
Oral immediate-release: 96-100%; oral sustained-release: 90-100% (relative to immediate-release, with dose dumping risk if formulation is altered).
Oral immediate-release: nearly 100%. Oral sustained-release: 80-100% depending on formulation. Rectal: variable (80-100%). Intravenous: 100%.
No routine adjustment needed. Monitor for accumulation in severe impairment (Cr Cl <10 m L/min) and consider reducing dose or extending interval.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min: reduce dose by 50% and monitor serum theophylline levels closely.
Child-Pugh Class A: reduce dose by 50%; Class B or C: reduce dose by 50-75% and monitor levels.
Child-Pugh Class A: reduce dose by 50%. Child-Pugh Class B: reduce dose by 75%. Child-Pugh Class C: use alternative therapy or reduce dose by 80-90% with close monitoring.
Children 1-9 years: 20-24 mg/kg/day orally divided every 12 hours; children 9-12 years: 20 mg/kg/day; adolescents 12-16 years: 18 mg/kg/day. Use ideal body weight. Adjust based on serum theophylline levels.
Loading dose: 5-6 mg/kg IV over 30 minutes. Maintenance IV infusion: age 1-6 months: 0.5 mg/kg/hour; 6-12 months: 0.6-0.7 mg/kg/hour; 1-9 years: 0.8-1.0 mg/kg/hour; >9 years: 0.5-0.7 mg/kg/hour. Oral: 5-6 mg/kg every 6 hours (immediate-release) or every 12 hours (extended-release).
Start at lower end of dosing range (e.g., 300 mg/day) due to decreased clearance. Titrate slowly and monitor serum concentrations. Avoid sustained-release formulations if hepatic impairment present.
Lower initial doses recommended (e.g., 300-400 mg/day oral) with slower titration, as clearance is decreased. Monitor serum theophylline levels and adjust to achieve 5-15 mcg/m L.
Theophylline has a narrow therapeutic index. Severe and fatal toxicities can occur if serum concentrations exceed 20 mcg/m L. Serum levels must be closely monitored during therapy.
Theophylline has a narrow therapeutic index; serum levels must be monitored. Severe toxicity can occur at levels above 20 mcg/m L, including seizures, cardiac arrhythmias, and death. Use with caution as serious adverse effects may occur without warning.
Serious and life-threatening adverse reactions including seizures and cardiac arrhythmias can occur at serum levels above 20 mcg/m L.,Concomitant use with other xanthine derivatives may increase toxicity.,Use with caution in patients with peptic ulcer, seizures, cardiac disease, or hepatic impairment.
Monitor serum theophylline levels; adjust dose accordingly,Risk of toxicity is increased in patients with hepatic impairment, congestive heart failure, cor pulmonale, and elderly patients,May exacerbate or induce peptic ulcer disease, seizures, and other cardiac arrhythmias,Concurrent use with other xanthines can increase toxicity,Smoking cessation decreases clearance and may require dose reduction
Hypersensitivity to theophylline or any component of the formulation,Uncontrolled seizure disorders,Active gastrointestinal hemorrhage
Hypersensitivity to theophylline or any component,Active seizure disorder unless adequately controlled with medications,Severe cardiac arrhythmias (e.g., ventricular tachycardia),Pregnancy (controversial; use only if clearly needed)
High-fat meals may reduce the rate of absorption but not extent; take consistently with or without food. Avoid charcoal-broiled foods and large amounts of dietary protein, which can increase clearance. Grapefruit juice may increase theophylline levels (minor effect).
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate stimulant effects and increase risk of toxicity. High-fat meals may slow absorption of extended-release formulations. No other significant food interactions.
SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theophylline crosses the placenta; maternal toxicity may cause fetal adverse effects such as transient tachycardia, jitteriness, and vomiting in neonates. Apnea and seizures reported in cases of maternal overdose.
Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of fetal tachycardia, jitteriness, and hypoglycemia due to maternal theophylline levels; no clear teratogenic signal. Close monitoring recommended.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6–0.7. The relative infant dose is about 10% of the maternal weight-adjusted dose. Although generally considered compatible with breastfeeding, monitor the infant for signs of irritability, insomnia, or poor feeding, especially at higher maternal doses or with multiple doses.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant serum levels are typically subtherapeutic, but irritability, jitteriness, and feeding intolerance have been reported. Caution advised; monitor infant for adverse effects. Benefit-risk assessment required.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased volume of distribution, potentially requiring dose increases of up to 20–40% to maintain therapeutic serum concentrations. However, clearance decreases near term and postpartum, necessitating dose reduction. Frequent monitoring of serum levels is critical to avoid toxicity.
Pregnancy increases theophylline clearance by 20-40% due to increased hepatic metabolism and renal blood flow. Monitor serum levels and adjust dose to maintain therapeutic range. Consider extended-release formulations for stable levels. Postpartum: clearance may decrease rapidly, requiring dose reduction.
SLO-BID (theophylline) requires serum level monitoring (therapeutic range 10-20 mcg/m L); levels >20 may cause toxicity. Use with caution in heart failure, hepatic impairment, or elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides increase levels; rifampin, phenytoin, smoking decrease levels. Sustained-release formulation avoids peak-trough fluctuations and improves adherence.
Aminophylline is a bronchodilator that contains theophylline and ethylenediamine. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Avoid use in patients with active peptic ulcer disease. Ethylenediamine component may cause allergic reactions in sensitive patients. Dose adjustment required in hepatic impairment, heart failure, or elderly. Tachyphylaxis may occur with prolonged use. Cigarette smoking increases clearance; monitor levels closely. Consider drug interactions with cimetidine, fluoroquinolones, and macrolides which decrease clearance.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, restlessness, insomnia, or rapid heartbeat.,Do not stop abruptly; taper under medical supervision to prevent rebound symptoms.,Maintain consistent timing; missed doses should be taken if remembered within 2 hours, otherwise skip.
Do not chew or crush extended-release tablets; swallow whole.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, rapid heartbeat, or seizures immediately.,Take this medication exactly as prescribed; do not change dose without consulting your doctor.,Inform your doctor if you have a history of seizures, ulcers, or liver disease.,Do not smoke or stop smoking without medical advice as it affects how this medication works.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-BID vs AMINOPHYLLINE DYE FREE, answered by our medical review team.
SLO-BID is a Xanthine Bronchodilator that works by Relaxes smooth muscle of bronchial airways and pulmonary blood vessels by inhibiting phosphodiesterase, increasing intracellular c AMP, and promoting bronchodilation.. AMINOPHYLLINE DYE FREE is a Xanthine Bronchodilator that works by Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular c AMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-BID and AMINOPHYLLINE DYE FREE depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-BID is: Dose: 300-600 mg orally every 12 hours. Immediate-release: 5 mg/kg loading dose then 3 mg/kg every 6 hours. Extended-release: 10-15 mg/kg/day divided every 12 hours. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AMINOPHYLLINE DYE FREE is: Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-BID and AMINOPHYLLINE DYE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-BID is classified as Category C. SLO-BID (theophylline) is classified as FDA Pregnancy Category C. First trimester: Limited human data, but no clear teratogenic pattern observed. Second and third trimesters: Theop. AMINOPHYLLINE DYE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Potential risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.